2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2162 Mezigdomide adds a multi-lineage activation and effector-differentiation program to BCMA T-cell engager therapy: Bone marrow and peripheral blood immune pharmacodynamics of elranatamab plus mezigdomide in relapsed/refractory multiple myeloma

Danny V. Jeyaraju, PhD, Jorge Fernandez2, Keyur Desai3, Yongliang Sun4, Luciano J. Costa, MD, PhD5, Nizar Bahlis, MD6, Guido Lancman, MD, MSc7, Kevin Hsu, PharmD8, Colin Godwin, MD9, Michael Burgess, MD, PhD10, Patrick Hagner11, Anita Gandhi, PhD12, Michael Amatangelo, PhD13
1 Bristol Myers Squibb, Princeton, NJ, United States
2 Bristol Myers Squibb, Princeton, United States
3 Bristol Myers Squibb, Princeton, NJ, United States
4 Bristol Myers Squibb, Princeton, NJ, United States
5 University of Alabama at Birmingham-the University of Alabama at Birmingham, Birmingham, Alabama, United States
6 Arnie Charbonneau Cancer Institute, Calgary, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Bristol Myers Squibb, Princeton, NJ, United States
9 Bristol Myers Squibb, Princeton, NJ, United States
10 Bristol Myers Squibb, Princeton, NJ, United States
11 Bristol Myers Squibb, Princeton, NJ, United States
12 Bristol Myers Squibb, Princeton, NJ, United States
13 Bristol Myers Squibb, Princeton, NJ, United States

Background: Bispecific T-cell engagers (TCEs) have improved the treatment of relapsed/refractory multiple myeloma (RRMM), but their effectiveness can be limited by T-cell dysfunction and exhaustion caused by chronic CD3 engagement. The presence of functional CD8 effector-memory cells and the absence of regulatory or exhausted T-cells is key to response to TCEs. Mezigdomide, a potent cereblon E3 ligase modulator (CELMoD), degrades Ikaros (IKZF1) and Aiolos (IKZF3), which are involved in T-cell exhaustion. Preclinical studies have shown that mezigdomide can reinvigorate the exhausted T cells and reduce the EC50 of BCMA bispecifics1. However, the patient-level pharmacodynamic effects of mezigdomide in combination with a BCMA TCE have not been extensively studied. In this work, we present translational results from the phase 1 CA057-1040 study, combining elranatamab and mezigdomide in RRMM.

Methods: In an on-going phase 1 study, RRMM patients (pts) received elranatamab plus mezigdomide (0.3 or 0.6 mg) in a combination regimen. Mezigdomide was added in Cycle 1 after the elranatamab step up dosing (Cycle 0). Paired pre/post treatment bone marrow (BM) samples (n=8 pts) and longitudinal peripheral blood (PB) samples (n=11 pts) were subjected to a 23-panel spectral flow analysis. The BM samples were collected at baseline and at C2D15. PB samples were collected longitudinally until C3D15. Various T-cell lineages (including CD8, conventional CD4, NKT, γδ T, and regulatory T-cells) as well as NK cells, were profiled for their activation, proliferation, cytotoxic/effector functions, checkpoint/exhaustion markers, and stem/memory (TCF1) markers. The changes in these markers relative to baseline were analyzed.

Results: On-target elranatamab activity was demonstrated by a near-complete depletion of circulating B-cells within the elranatamab step up dosing. Mezigdomide stimulated a broad activation of immune cells that extended beyond the CD8 compartment. This was evident from the concordant rise in the activation markers, HLA-DR and ICOS across CD8, conventional CD4, NKT, and γδ T cells in the bone marrow (e.g., CD8 HLA-DR increased by 32% and ICOS by 30%) indicating mezigdomide's immunostimulatory effect is pan-lymphocyte rather than confined to the CD8 cytotoxic effector pool.

In the peripheral blood, CD38, a marker of T-cell activation, increased by approximately 20–35% across all four T-cell lineages (Naïve, central memory, effector memory and terminally differentiated effector memory T cells (TEMRA)), suggesting a shared, drug-driven signal rather than a lineage-restricted response. This activation was accompanied by cytotoxic programming, with increased expression of T-bet, granzyme B, and perforin in both CD8 and innate-like NKT/γδ T cells. In addition, there was a shift in differentiation state, with naïve/TEMRA subsets contracting while effector-memory (EM) cells expanded. In the bone marrow, CD8 EM rose from roughly from 50% to 66% of the CD8+ T-cells by C2D15, while in peripheral blood, it increased from 42% to 78%. Concurrently, stem-like TCF1 declined across all memory subsets, most prominently in the less-differentiated naïve and central-memory pools, while activation and cytotoxic markers rose most in EM; proliferation (Ki-67) did not concentrate consistently in any single subset across the combined cohort. This pattern is consistent with mezigdomide promoting differentiation of memory precursors into effectors alongside contraction of the naïve/central-memory pool.

Conclusions: Adding mezigdomide to elranatamab reprograms the immune compartment through broad, multi-lineage activation and conversion of memory T cells into cytotoxic effectors with a stronger effect at the 0.6 mg dose of mezigdomide. This pattern is consistent with the immunostimulatory activity previously described for CELMoDs2 and provides a mechanistic rationale for this combination. Correlation of this pharmacodynamic signature with depth and durability of clinical response in larger cohorts will help define its translational significance.

 

References: 

Chiu et al., Blood 2026 Amatangelo et al., Cell Rep Med. 2024
Danny V. Jeyaraju, PhD: Bristol Myers Squibb - Current equity holder in publicly-traded company; Bristol Myers Squibb - Current Employment